Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | KDM4A | O75164 | 3/20 | 0.44 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | ASPH | Q12797 | 1/20 | 0.41 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.41 |
| ▸ | KDM5A | P29375 | 8/20 | 0.40 |
| ▸ | KDM5B | Q9UGL1 | 6/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 4/20 | 0.40 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | KDM6B | O15054 | 1/20 | 0.37 |
| ▸ | KDM6A | O15550 | 1/20 | 0.37 |
| ▸ | TET3 | O43151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29918869 | 1.00 | KDM4E (0.44) | KDM4EKDM4AEGLN1L3MBTL1RAB9A | |
| SCHEMBL21997997 | 0.80 | PSMD14 (0.43) | KDM4EL3MBTL1ALDH1A1LMNAKDM5A | |
| SCHEMBL29918750 | 0.80 | PSMD14 (0.43) | KDM4EL3MBTL1ALDH1A1LMNAKDM5A | |
| SCHEMBL14361288 | 0.75 | ALDH1A1 (0.34) | KDM4ERAB9AALDH1A1LMNAMCL1 | |
| SCHEMBL2455911 | 0.74 | KDM4E (0.52) | KDM4EKDM4AEGLN1L3MBTL1RAB9A | |
| SCHEMBL28512682 | 0.74 | KDM4E (0.57) | KDM4EKDM4AEGLN1L3MBTL1RAB9A | |
| SCHEMBL24186148 | 0.74 | ALDH1A1 (0.59) | KDM4EKDM4AEGLN1L3MBTL1RAB9A | |
| SCHEMBL15884240 | 0.72 | NQO2 (0.36) | KDM4E | |
| SCHEMBL3112943 | 0.72 | KDM4E (0.34) | KDM4EL3MBTL1ALDH1A1LMNAALOX12 | |
| SCHEMBL5262547 | 0.72 | NCF1 (0.39) | KDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163042-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| US-20240239777-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-11807636-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11807636-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20230219945-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230219945-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230219945-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| US-11352350-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-11352350-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
| EP-3886904-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2021-10-06 | — | — | EP | disclosed |
| CN-113423427-A | IRAK degrading agents and uses thereof | 凯麦拉医疗公司 | 2021-09-21 | — | — | CN | disclosed |
| US-11117889-B1 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| US-11117889-B1 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| WO-2021127278-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2020113233-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163042-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | KDM4E 190/4885KDM4A 104/4885EGLN1 1276/4885 |
| US-11117889-B1 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | KDM4E 190/4885KDM4A 104/4885EGLN1 1276/4885 |
| US-11352350-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | KDM4E 190/4885KDM4A 104/4885EGLN1 1276/4885 |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | KDM4E 190/4885KDM4A 104/4885EGLN1 1276/4885 |
| US-20230219945-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | KDM4E 190/4885KDM4A 104/4885EGLN1 1276/4885 |
| US-20240239777-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | KDM4E 190/4885KDM4A 104/4885EGLN1 1276/4885 |
| US-11807636-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | KDM4E 190/4885KDM4A 104/4885EGLN1 1276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.